NCT03280927

Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis

A Multicenter, Open-label, Non-controlled, Single-arm Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 97 (actual)
• Sponsor: Dong-A ST Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The antifungal efficacy and safety of Jublia® topical solution will be assessed through an administration for 48 weeks to patients diagnosed with a mild or moderate onychomycosis due to dermatophyte.

Detailed description

Evaluate anti-fungal activity and safety of efinaconazole in patients with mild to moderate toenail onychomycosis caused by dermatophytes that received a 48-week administration of efinaconazole.

Conditions

• Mild to Moderate Onychomycosis Due to Dermatophyte

Interventions

Type	Name	Description
DRUG	Jublia®	Jublia® topical solution

Timeline

• Start date: 2017-11-10
• Primary completion: 2020-01-22
• Completion: 2020-01-22
• First posted: 2017-09-13
• Last updated: 2021-04-27

Locations

1 site across 1 country: South Korea